Companies that market medical devices across multiple international markets are familiar with the growing importance of UDI systems. While the EU relies on EUDAMED, the United States uses GUDID, and Australia is introducing its own UDI system through AusUDID, New Zealand currently does not operate a UDI database.
Nevertheless, MedTech companies should closely monitor regulatory developments. On the one hand, New Zealand’s medical device regulatory framework is undergoing significant changes. On the other hand, the country’s close economic relationship with Australia means that UDI requirements are already indirectly relevant for many manufacturers today.
Is UDI Mandatory in New Zealand?
No. Currently, there is no legal requirement to implement Unique Device Identification (UDI) for medical devices in New Zealand. Manufacturers are not required to submit UDI data to a national database or apply UDI codes to products and packaging.
Unlike markets such as the European Union, the United States, or Australia, New Zealand currently has no centralized UDI database. However, this does not mean that medical devices are unregulated. National market access requirements still apply, particularly registration through the WAND system (Web Assisted Notification of Devices).
Regulatory Framework for Medical Devices in New Zealand
The regulatory basis for medical devices in New Zealand continues to be the Medicines Act 1981 and its associated regulations. As a result, New Zealand operates one of the oldest regulatory systems for medical devices among established MedTech markets.
The responsible authority is Medsafe, New Zealand’s medicines and medical devices regulator. Medsafe oversees the medical device market and operates the national WAND database.
Although a major regulatory reform had been planned in recent years, it has been put on hold for the time being.
The Failed Reform of 2023
The Therapeutic Products Act 2023 was intended to introduce a modern regulatory model more closely aligned with international standards. While the legislation was approved by Parliament in 2023, it was repealed following a change of government before most provisions could come into effect. The corresponding Repeal Bill was passed on December 13, 2024.
Medical Products Bill as the Successor
The government is currently working on a new Medical Products Bill, which is intended to replace the Medicines Act in the long term. Based on the publicly available legislative agenda, there are currently no specific provisions requiring the introduction of a UDI system. Whether UDI may become part of the new regulatory framework remains uncertain.
WAND: New Zealand’s Medical Device Database
Even without a UDI system, medical devices must be notified in New Zealand. For this purpose, Medsafe uses the WAND system (Web Assisted Notification of Devices).
However, WAND differs fundamentally from databases such as EUDAMED or AusUDID:
- No UDI data submission
- No government product approval
- No pre-market review by Medsafe
- No conformity assessment as part of registration
The database serves exclusively as a market surveillance tool. It enables Medsafe to quickly identify and contact affected companies in the event of safety concerns, recalls, or field safety corrective actions.
Which Information Is Collected in WAND?
As part of the notification process, the following information is typically recorded:
- Manufacturer name and address
- Device description
- GMDN code
- Intended purpose
- Risk classification
- Sterilization information, where applicable
A UDI and the submission of UDI-based master data are currently not required.
UDI New Zealand: What Manufacturers Need to Consider
Although there are no national UDI requirements, several regulatory obligations remain relevant.
Appoint a Local Sponsor: Foreign manufacturers must appoint a sponsor based in New Zealand. The sponsor serves as the primary contact for Medsafe and is responsible for regulatory compliance.
Register Products in WAND: The sponsor must notify products in WAND within 30 working days after market placement. Any changes to the recorded information must also be reported promptly to Medsafe.
Ensure Correct Classification: Even though no formal review is conducted by the authority, manufacturers and sponsors remain responsible for the correct risk classification and compliance with applicable requirements.
Monitor Regulatory Developments: As the future Medical Products Bill has not yet been finalized, companies should continue to closely monitor regulatory developments in New Zealand.
Why UDI Is Still Relevant in New Zealand
For many international manufacturers, regulatory considerations do not end at New Zealand’s borders.
New Zealand and Australia form a closely integrated economic area through the Trans-Tasman Mutual Recognition Arrangement (TTMRA). Many MedTech companies serve both markets and harmonize their registration and labeling processes accordingly.
While New Zealand currently has no UDI requirements, Australia is gradually implementing its national UDI system:
- July 1, 2026: Class III and Class IIb devices
- July 2027: Class IIa devices
- July 2028: Class Is devices and certain IVD products
- July 2029: Additional IVD classes
As a result, many manufacturers already need to align their product data, labeling, and processes with UDI requirements, even if they also market products in New Zealand.
Timeline: Key UDI Developments in New Zealand
1981: Medicines Act 1981 enters into force and remains the legal basis for medical devices.
2003: Introduction of the WAND database through the Medicines (Database of Medical Devices) Regulations 2003.
2023: Therapeutic Products Act 2023 is adopted to modernize medical device regulation.
December 13, 2024: The new government repeals the Therapeutic Products Act before its core provisions can take effect.
2025 to 2026: Development of the new Medical Products Bill.
From 2028 (expected): Possible entry into force of the new medical device legislation. No concrete plans regarding a UDI requirement have been announced so far.
UDI New Zealand Remains a Future Topic
UDI is currently not a regulatory requirement in New Zealand. Manufacturers are not required to implement UDI labeling or submit data to a national UDI database. Instead, the current system is based on WAND registration and comparatively light-touch market surveillance.
For internationally active MedTech companies, however, the topic remains highly relevant. Due to the rollout of AusUDID in Australia and the ongoing reform of New Zealand’s medical device regulations, it is worthwhile to establish UDI processes strategically today. Companies that centrally manage product data and coordinate regulatory requirements across multiple markets will be better prepared for future developments. An AusUDID-ready solution such as the UDI Manager therefore provides an ideal foundation for potential future regulations in New Zealand.